rdf:type |
|
lifeskim:mentions |
umls-concept:C0017119,
umls-concept:C0017132,
umls-concept:C0021469,
umls-concept:C0030685,
umls-concept:C0031809,
umls-concept:C0037659,
umls-concept:C0061355,
umls-concept:C0063684,
umls-concept:C0215825,
umls-concept:C0231491,
umls-concept:C0243071,
umls-concept:C0391871,
umls-concept:C0441472,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1314939,
umls-concept:C1963578
|
pubmed:issue |
5
|
pubmed:dateCreated |
1999-2-26
|
pubmed:abstractText |
1. The effect of a new type 2 selective somatostatin (SRIF) receptor antagonist (DC-41-33) on somatostatin-induced inhibition of pentagastrin-stimulated gastric acid secretion in conscious, chronic gastric fistula equipped rats was studied. 2. Infused intravenously, DC-41-33 dose-dependently inhibits SRIF-induced inhibition of pentagastrin-stimulated gastric acid secretion with an IC50 of 31.6+/-1.2 nmol kg(-1) versus 10 nmol kg(-1) SRIF and blocks the inhibitory effects of SRIF when simultaneously co-infused. Its effectiveness provides additional evidence that SRIF-inhibition of gastric acid release is a SRIF type 2 receptor-mediated process. 3. DC-41-33 is able to completely reverse the inhibitory effect of glucose-dependent insulinotropic polypeptides, GIP and GIP-(1-30)NH2, and glucagon-like polypeptide, GLP-1(7-36)NH2, on pentagastrin-stimulated gastric acid secretion thus confirming that they exert these effects through stimulation of endogenous SRIF release. 4. DC-41-33 only partially blocks potent amylin and adrenomedullin-induced inhibition of gastric acid secretion, therefore suggesting that somatostatin may not function as a primary mediator in the action of these peptides. 5. Our results indicate that DC-41-33, is a potent in vivo inhibitor of exogenous and endogenous SRIF in rats. It represents a new class of SRIF analogues which should eventually provide excellent tools for further evaluating the many physiological roles of SRIF and its five receptor subtypes.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenomedullin,
http://linkedlifedata.com/resource/pubmed/chemical/Amyloid,
http://linkedlifedata.com/resource/pubmed/chemical/Gastric Inhibitory Polypeptide,
http://linkedlifedata.com/resource/pubmed/chemical/Gastrointestinal Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon-Like Peptide 1,
http://linkedlifedata.com/resource/pubmed/chemical/Islet Amyloid Polypeptide,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Precursors,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Somatostatin,
http://linkedlifedata.com/resource/pubmed/chemical/Somatostatin,
http://linkedlifedata.com/resource/pubmed/chemical/somatostatin receptor 2
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0007-1188
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
125
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1081-7
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:9846648-Adrenomedullin,
pubmed-meshheading:9846648-Amyloid,
pubmed-meshheading:9846648-Animals,
pubmed-meshheading:9846648-Dose-Response Relationship, Drug,
pubmed-meshheading:9846648-Gastric Acid,
pubmed-meshheading:9846648-Gastric Inhibitory Polypeptide,
pubmed-meshheading:9846648-Gastrointestinal Hormones,
pubmed-meshheading:9846648-Glucagon,
pubmed-meshheading:9846648-Glucagon-Like Peptide 1,
pubmed-meshheading:9846648-Islet Amyloid Polypeptide,
pubmed-meshheading:9846648-Male,
pubmed-meshheading:9846648-Peptide Fragments,
pubmed-meshheading:9846648-Peptides,
pubmed-meshheading:9846648-Protein Precursors,
pubmed-meshheading:9846648-Rats,
pubmed-meshheading:9846648-Receptors, Somatostatin,
pubmed-meshheading:9846648-Somatostatin
|
pubmed:year |
1998
|
pubmed:articleTitle |
Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin and adrenomedullin on gastric acid release using a new SRIF antagonist analogue.
|
pubmed:affiliation |
Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112-2699, USA.
|
pubmed:publicationType |
Journal Article
|